The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight. In report published in Nature Medicine, Dr. Ziyad Al-Aly, chief of research and development at the VA St. Louis Health Care System and clinical epidemiologist at Washington University School of Medicine, and his colleagues performed a comprehensive analysis on the health outcomes associated with the drugs known as GLP-1 receptor agonists.